Published in Women's Health Weekly, November 13th, 1995
The HER-2/neu Genetic Test System is intended to aid physicians in predicting the likelihood of disease recurrence in women who have been initially diagnosed with breast cancer. Prediction, or prognosis, of breast cancer recurrence will assist physicians and patients in making better informed therapeutic decisions.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly